The global prinzmetal angina therapeutics market is expected to surpass an impressive valuation of US$ 10.7 Billion in 2023 and is projected to reach US$ 17.2 Billion by 2033, trailing a CAGR of 4.85%. A major driving factor is a rise in the patient population suffering from cardiac disorders such as coronary heart disease. For instance, as per the data published by the World Health Organization, in December 2020, ischemic heart disease was the world's leading cause of death, accounting for around 16 percent of all deaths. This disease has shown the highest increase in deaths since 2000, increasing by more than 2 million to 8.9 million deaths in 2020.
Stroke and chronic obstructive pulmonary disease (COPD) are the second and third largest causes of death, accounting for around 11% and 6% of all deaths, respectively. In addition, an article titled "Angina: contemporary diagnosis and management" published in PubMed Central, in February 2020, stated that Ischemic heart disease (IHD) continues to be the largest cause of death and lost life years in adults, particularly among women under the age of 55. Angina pectoris is a typical clinical manifestation of IHD and is chest discomfort caused by a heart attack. Therefore, the rising number of patients suffering from IHD is likely to impel the market growth for angina pectoris drugs over the forecast period, thereby driving market growth. However, the growing adoption of minimally invasive surgeries and side effects associated with certain drug classes are some of the factors that may restrain the market's growth in the coming years.
For instance, as per a study titled "Long COVID-19 and microvascular disease-related angina" published in Sociedad Española de Cardiología, in November 2021, after meticulous evaluation and exclusion of other illnesses, the researchers found that 27.1% of the patients evaluated in a long COVID-19 unit had chest pain, some of which was suggestive of angina. A total of 186 patients were enrolled in the trial, 51 (27%) of whom reported ongoing chest pain after being examined in the long COVID-19 unit. Thus, such studies highlighted the need for drugs to manage angina pectoris in COVID-19 patients, ultimately boosting the demand for targeted drugs. Therefore, the rising number of COVID-19 patients with cardiological complications is likely to boost the market's growth over the forecast period.
Furthermore, factors driving the market growth include the rising burden of lifestyle diseases, especially cardiac disorders; technological advancements towards personalized cardiovascular medicine; and the advancement in novel drug delivery systems.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 10.7 Billion |
| Anticipated Forecast Value (2033) | US$ 17.2 Billion |
| Projected Growth Rate (2023 to 2033) | CAGR 4.85% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The prinzmetal angina therapeutics market was valued at US$ 9.08 Billion in 2018 while growing at a CAGR of 2.65% during the historical period. The advent of Novel target drugs and therapies gaining traction like Factor Xa Inhibitors, monoclonal antibodies, and gene therapy are boosting the therapeutics market.
Considering these factors, the Prinzmetal Angina therapeutics market is projected to reach US$ 17.2 Billion, while exhibiting a CAGR of 4.85% during the forecast period.
Emerging therapies to propel market growth
New therapies entering the market will be the main drivers of growth, with one gene-based therapy, Generx (Ad5FGF-4), and two cell-therapy treatments, CLBS16 and CLBS14 anticipated to launch in the US during the forecast period. Other major drivers for the angina market are the aging global population, enhanced survival after an MI, and the rising prevalence of obesity, diabetes, and hypertension. Moreover, diagnosed cases of prinzmetal angina will grow at a CAGR of 16.5% during the forecast period which will directly benefit market expansion.
Principal Consultant
High cost of treatment to restrain product demand
The high cost associated with the treatment and the regular uncertainty seen in reimbursement policies are the factors expected to restrict Prinzmetal Angina therapeutics market growth. A rise in concerns regarding side effects on the body is projected to challenge the Prinzmetal Angina market in the forecast period of 2023 to 2033.
On the other hand, non-adherence to cardiovascular medications has been observed among patients with cardiovascular diseases buying generic medicines instead of specific branded drugs is anticipated to hamper the market growth.
North America dominates the angina pectoris drugs market with a market share of around 42%, due to the established healthcare infrastructure, rising adoption of therapeutics, and the presence of key manufacturers in the USA, which is responsible for its large share. Ischemic heart disease is a major cause of death and disability within the North American region, while angina represents its most common symptom.
For instance, as per the data published by the National Center for Chronic Disease Prevention and Health Promotion, Division for Heart Disease and Stroke Prevention, in February 2022, the most frequent type of heart disease, ischemic heart disease, claimed around 360,900 individual lives in 2020. Coronary artery disease affects approximately 18.2 million persons aged 20 and older. Adults under the age of 65 account for about 2 out of every 10 deaths due to coronary artery disease.
Similarly, an article titled "Ischemic Heart Disease: Noninvasive Imaging Techniques and Findings" published in RSNA (RadioGraphics), in May 2021, stated that in the United States alone, the annual incidence of new coronary events is around 720,000 instances, and the current prevalence of ischemic heart disease is around 18.3 million cases.
Thus, such a higher prevalence of heart disease is likely to increase the incidence of angina pectoris, thereby fueling demand for angina pectoris drugs within the region. Moreover, the rise in the number of clinical trials is also fueling the market's growth. For instance, as of April 2022, there were 23 active and recruiting clinical trials for angina pectoris within the United States. Therefore, these factors together contribute to the expansion of the angina pectoris drug market throughout the analysis period.
The USA dominated the region by accounting for more than 40% of the market share in 2022. Established healthcare infrastructure, growing adoption of therapeutics, and presence of key manufacturers are responsible for its larger share. Also, the rising incidence of cardiac disorders due to a sedentary lifestyle and favorable regulatory initiatives are propelling the market growth.
Changing regulatory scenario in the USA is expected to impact clinical trials of Advanced Therapy Medicinal Products. Multiple gene therapy products in Phase II/III trials are emerging as a novel approach toward addressing the need for non-surgical cardiovascular treatments. Taxus Cardium’s adenovector (serotype 5) DNA-based gene therapy is currently undergoing late-stage clinical trials and could present promising growth opportunities for the market in the forecast period.
South Asia is estimated to be the fastest growing region for the angina market owing to the presence of developing economies such as India and China and a developing healthcare sector. This region is projected to witness growth with a CAGR of 4%. Increasing healthcare expenditure and favorable government policies are also anticipated to boost Angina's Market growth during the forecast period.
China offers robust opportunities for market expansion due to the removal of price caps on all medicine categories, the ongoing Healthy China 2020 healthcare reform, and supportive 12th Five-Year Plan measures that target biotechnology as a key development sector. Furthermore, the presence of a large target population and robust unmet clinical needs are some of the factors that are expected to fuel growth in this region.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In patients with stable angina caused by CAD, beta-blockers are considered first-line therapy. The segment's growth is majorly attributed to an increase in the target population and a rising number of strategic developments among market players for increasing the commercial availability of beta-blocker drugs.
For instance, in April 2022, New American Therapeutics provided Melinta Therapeutics with the right to TOPROL-XL (metoprolol succinate) in the United States. TOPROL-XL is a cardio-selective beta-blocker that has been approved by the FDA for the treatment of hypertension, either alone or in combination with other antihypertensives, as well as the long-term treatment of angina pectoris and the treatment of stable, symptomatic heart failure of specific causes. Such developments will strengthen the segment's growth in the forecast period.
The hospital Pharmacies segment is projected to account for a segment share of 55% during the forecast period. This is mostly due to an increase in the number of patients with illnesses that require treatment in hospitals with modern infrastructure and suitable amenities. Furthermore, the expanding number of hospitals, as well as sufficient reimbursement rules, are both contributing to the segment's growth.
Key players in the prinzmetal angina therapeutics market are: Sanofi S.A., Gilead Sciences; Inc., AstraZeneca Plc, Pfizer; Inc., Eli Lilly, and Company, Amgen; Inc., GlaxoSmithKline Plc, Tasly Pharmaceuticals; Inc., Novartis AG, XyloCor Therapeutics
Some recent developments in this industry are:
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 10.7 Billion |
| Market Value in 2033 | US$ 17.2 Billion |
| Growth Rate | CAGR of 4.85% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in US$ Billion and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class, Disease Type, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, China, Japan, Malaysia, Singapore, Thailand, South Korea, Australia, New Zealand, United Arab Emirates(UAE), GCC Countries, South Africa, Israel |
| Key Companies Profiled | Sanofi S.A.; Gilead Sciences Inc.; AstraZeneca Plc; Pfizer Inc.; Eli Lilly and Company; Amgen Inc.; GlaxoSmithKline Plc; Tasly Pharmaceuticals Inc.; Novartis AG; XyloCor Therapeutics |
| Customization | Available Upon Request |
The market is estimated to rise at a 4.85% CAGR through 2033.
The top 3 market players are Sanofi S.A., Gilead Sciences; Inc., and AstraZeneca Plc,
The emergence of novel therapies propels market growth.
The market is valued at US$ 10.7 billion in 2023.
The market is expected to reach US$ 17.2 billion by 2033.
1. Executive Summary | Prinzmetal Angina Therapeutics Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Beta Blockers 5.3.2. Calcium Antagonists 5.3.3. Anti-coagulants 5.3.4. Anti-Platelets 5.3.5. Anti-Anginal 5.3.6. ACE inhibitors 5.3.7. Nitrates 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033 6.3.1. Stable or chronic angina 6.3.2. Unstable angina 6.3.3. Variant and microvascular angina 6.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Online pharmacies 7.3.2. Hospital pharmacies 7.3.3. Retail pharmacies 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. Middle East and Africa(MEA) 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Disease Type 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Disease Type 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Disease Type 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Disease Type 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Disease Type 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Disease Type 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Class 12.2.3. By Disease Type 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Disease Type 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By Disease Type 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Disease Type 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Class 14.2.3. By Disease Type 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Disease Type 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of Middle East and Africa(MEA) 15.2.2. By Drug Class 15.2.3. By Disease Type 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Disease Type 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Class 16.1.2.2. By Disease Type 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Class 16.2.2.2. By Disease Type 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Class 16.3.2.2. By Disease Type 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Class 16.4.2.2. By Disease Type 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Class 16.5.2.2. By Disease Type 16.5.2.3. By Distribution Channel 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Class 16.6.2.2. By Disease Type 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Class 16.7.2.2. By Disease Type 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Class 16.8.2.2. By Disease Type 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Class 16.9.2.2. By Disease Type 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Class 16.10.2.2. By Disease Type 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Class 16.11.2.2. By Disease Type 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Class 16.12.2.2. By Disease Type 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Class 16.13.2.2. By Disease Type 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Class 16.14.2.2. By Disease Type 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Class 16.15.2.2. By Disease Type 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Class 16.16.2.2. By Disease Type 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Class 16.17.2.2. By Disease Type 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Class 16.18.2.2. By Disease Type 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Class 16.19.2.2. By Disease Type 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Class 16.20.2.2. By Disease Type 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Class 16.21.2.2. By Disease Type 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Disease Type 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Sanofi S.A. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Gilead Sciences; Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. AstraZeneca Plc 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Pfizer; Inc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Eli Lilly and Company 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Amgen; Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. GlaxoSmithKline Plc. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Tasly Pharmaceuticals; Inc. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Novartis AG 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. XyloCor Therapeutics 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Prinzmetal Angina Therapeutics Market
